Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE
2023-505705-17-00Phase 4Authorised
- Sponsor
- Deventer Ziekenhuis
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxycodone and abiraterone in prostate cancer (PCa) and pain (2 arms), sponsored by Deventer Ziekenhuis. Planned start Aug 2023; status: authorised.
02
Drugs
oxycodoneabiraterone
03
Conditions
prostate cancer (PCa)pain
Beyond the preview
Go deeper on 2023-505705-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505705-17-00.